Screening for Cross-Reactivity and Validation of Peptide-Centric CAR-T Cells for Neuroblastoma using MHC Dextramer®
Maximize the Potential of Cell Therapy
Explore how Dextramer® reagents support the development and manufacturing of effective cellular immunotherapies.
Monitor Antigen Specificity
Specificity can be key to successful immune cell therapy. Immudex provides high-quality Dextramer® reagents that enable precision cellular immune monitoring of antigen-specific cells for advanced cell therapy.
Reagents for Development and Manufacturing
Immudex is committed to providing Dextramer® and Xynapse™ reagents for development and release testing of cell therapy products.
Reagents for Quality Control of Cell Therapy Drug Products
Immudex provides MHC Dextramer® (GMP) reagents produced in compliance with international GMP standards. Applications include quality control of cell therapy drug products and analysis of samples from clinical trials.
CAR Cell Therapy
Dextramer® technology enables the creation of customized multimers that bind with high avidity to your CAR target of choice. This technology supports direct detection and quantification of CAR cells with high sensitivity. Barcode-enabled dCODE Dextramer® reagents further allow in-depth characterization of CAR cells at the single-cell level.
DOWNLOAD BROCHURE
Dextramer® Reagents Enable TCR Discovery
Immudex provides high-quality barcoded dCODE Dextramer® reagents that enable TCR discovery by single cell analysis. We also offer TCR Solutions for the validation and characterization of candidate TCRs.
Download TCR Discovery Application Note
TCR-T Cell Therapy
Explore the wide range of cellular immunotherapies, including approved therapies, and learn more about TCR-based immunotherapies and the diseases to which they are applied. We highlight why a thorough understanding of the antigen-specific interaction is critical for the development of effective TCR-T therapeutics, and explain how Immudex’s products including Dextramer® technology and TCR Solutions can support the development and manufacturing of these therapies.
DOWNLOAD APPLICATION NOTE
Xynapse™-T Reagents for Development and Potency Testing of TCR-T Cell Therapies
Antigen presenting cells (APCs) are used to characterize transgenic TCR candidates during cell therapy development. They are also a critical component of potency assays of TCR-T cell therapy drug products in connection with product release testing. However, assays based on living APCs are intrinsically associated with high variability. In addition, their preparation and maintenance are labor-intensive.
Xynapse™-T are convenient synthetic antigen presenting molecules that can replace APCs in multiple applications including potency testing.
Learn more
Release Testing of TCR-T Cell Therapies
Immudex provides high-quality Dextramer® reagents that enable precision cellular immune monitoring of antigen-specific cells.
Dextramer® technology can characterize and validate antigen-specific cell therapy products with high resolution and is applied during release testing of cell products.
Read More
Explore Case Studies – Applications of Dextramer® Technology in Cell Therapy
Assessing the HLA-Specificity of CAR-T Cells with MHC I Dextramer® Reagents
Plasmacytoid Dendritic Cell Line-Based Vaccine Primes and Expands Antitumor T Cells in Melanoma Patients
A TCR-Accepting T-Cell Platform to Profile Tumor-Specific T-Cell Receptors
Cancer Neoepitopes for Immunotherapy: Strategies for Adoptive T-Cell Therapy
Identification of Epitopes that Pose as Attractive Targets for Vaccination and Other T-Cell Therapies with Klickmer®
Relevant Products and Services
CAR Dextramer®
Our team can provide you with Custom CAR Dextramer® reagents to match your target antigen.
T Cell Stimulation
Antigen-specific activation of immune cells using novel Xynapse™ reagents.
Further Resources
CAR Staining Reagents
Explore why high avidity reagents are important for CAR cell detection.
CAR Cell Therapy Brochure
Learn how CAR Dextramer® technology enables superior detection and characterization of CAR cells.
TCR-T Cell Therapy Milestones
Read our blogs on key milestones including approval of the first TCR-T cell therapy for solid tumors.
TCR-T Cell Therapy Brochure
Discover how Dextramer® technology can support, from epitope and TCR discovery, to release testing and immune monitoring.
Want to Hear More About Our Cell Therapy Solutions?
Fill in the form and one of our dedicated specialists will get in touch with you shortly